Email: email@example.com Call toll free: 800-411-1222(TTY 866-411-1010)Se habla español.More contact info
Healthy people can help us better understand, treat, and prevent diseases. Complete an online screener if you want to volunteer for a clinical research study.
Safety, Tolerability, and Efficacy of Daclatasvir and Asunaprevir, with or without BMS-791325, in Subjects Coinfected with HIV- HCV
You are being asked to participate in this study because you have HIV infection and liver disease caused by infection with hepatitis C virus (HCV). Your blood tests show that the HCV infection continues to be a problem (i.e., the virus continues to reproduce), causing a chronic infection. Currently there are about 4 million people with HCV in the United States and only about 10 to 20 percent are being treated for their HCV.
Daclatasvir (DCV), asunaprevir (ASV), and BMS-791325 are new oral medications being developed for the treatment of HCV infection. They are still being researched and are not approved by the Food and Drug Administration (FDA). This combination of ASV, DCV, and BMS-791325 has never been given to individuals with both HIV and HCV infection. The purpose of this study is to determine whether this combination of drugs for 12 weeks can be safe and effective for treating HCV infection in people who also have HIV infection.
DCV, ASV, and BMS-791325 work by blocking the HCV from making new copies of itself in your body. These drugs have been used along with other medications commonly used to treat HCV such as interferon (IFN) and ribavirin (RBV). As of October 2013, more than 1,000 healthy volunteers, as well as people with HCV, have taken this combination of drugs as part of research studies. When used with IFN and RBV, these drugs seem to be very effective in eliminating HCV from the body. However, IFN (given as weekly injection) and RBV (pills taken twice a day) are associated with several serious side effects. The development of drugs that may cure HCV infection without using IFN or RBV would be extremely beneficial for the large number of patients infected with HCV.
This study will enroll 20 people who have both HIV and HCV type 1b. Once enrolled you would receive 24 weeks of ASV and DCV. We do not yet know for sure if we can treat the difficult cases of HCV, such a type 1b, seen in people who also have HIV, with pills alone, instead of the usual combination of pills and IFN injections.
This study will enroll 20 people who have both HIV and HCV type 1. Once enrolled, you would receive 12 weeks of DCV, ASV, and BMS-79135.
One fixed-dose combination pill (FDC, which is a combination of DCV (30 mg), ASV (200 mg), and BMS-791325 (75mg) will be taken twice a day with food. Bristol-Myers Squibb, Inc., the manufacturer, will provide this combination pill to NIH. Participants will be followed during the treatment and for 48 weeks afterwards. After starting the study drugs, if you have to stop them for any reason, you will be offered evaluation for HCV treatment (which will contain interferon, RBV, and another drug that blocks HCV called HCV protease inhibitors) under another clinical study, should you choose to take part.
Your participation in the study involves multiple visits to NIH only, or NIH and the DC community clinics over a period of one year and five months from the start of study treatment. In general, each visit will require collection of blood and urine to be used for safety labs (blood counts, blood clotting tests, kidney function, muscle and liver tests, blood minerals, and electrolytes), as well as labs to determine the amount of HCV in your blood (HCV viral load), levels of the study drugs (DCV, ASV, and BMS-791325) your CD4 count, and your HIV viral load. All these tests are routine for patients with infections like yours, but we will need to do them much more often. A liver biopsy may be required prior to the start of the study if you have not had one within three years.
Last Updated February 13, 2015